Promising Flavonoid‐Fused Aminoquinolines as Synthetic Alzheimer's Disease Models: Design, Synthesis, Anticholinesterase Activity, ADMET and Molecular Docking

An efficient one‐pot, two‐step [4 + 2] cyclocondensation reaction of (±)‐2‐phenylchroman‐4‐ones ( 1 ) with various scaffolds of 2‐aminobenzonitriles ( 2 ) was employed using AlCl 3 as the catalyst in the presence of toluene as a solvent under conventional thermal heating. This method was used to synthesize a series of six novel examples of (±)‐7‐amino‐6‐aryl‐6 H ‐chromeno[4,3‐ b ]quinolines ( 3 ), which were designed as potential cholinesterase inhibitors. Subsequently, the new chromeno[4,3‐ b ]quinolines were evaluated for their AChE and BChE inhibitory activity and subjected to molecular docking studies. In vitro cholinesterase assays and in silico docking demonstrated that all newly modified tacrine analogs 3 exhibited higher Hs BChE inhibitory activity compared to Hs AChE. Specifically, the most effective human cholinesterase inhibitor was the compound (±)‐7‐amino‐6‐phenyl‐6 H ‐chromeno[4,3‐ b ]quinoline ( 3aa ), with an IC 50 of 2.73 μM for Hs AChE and 0.096 μM for Hs BChE. These findings suggest that compound 3aa is a promising candidate for further assessment in synthetic Alzheimer's disease models.